GILD News and Press, Gilead Sciences Inc. From 06/20/24

– First Phase 3 HIV Prevention Trial Ever to Show Zero Infections – – Independent Data Monitoring Committee Recommended That Gilead Stop the Blinded Phase of the PURPOSE 1 Trial at Interim Analysis and Offer Open-Label Lenacapavir to All Participants – ...

2024-06-20 08:45:59 ET Palm Beach, FL – June 20, 2024  – Pancreatic cancer is among the most frequently diagnosed and the seventh leading cause of cancer death globally. Pancreatic cancer becomes more common in the Western world. The prevalence rate of pancreatic adenocar...

NORTHAMPTON, MA / ACCESSWIRE / June 19, 2024 / Gilead Sciences Gilead and Kite Pharma teams raised Pride Month flags at our campuses last week symbolizing our united support for LGBTQ+ communities globally. Our commitment to inclusion and diversity is vital to our mission and will help us cre...

2024-06-18 16:03:19 ET Summary Roche continues to face challenges tied to lackluster revenue and profit outlook, questionable pipeline, and an underperforming diagnostics business. Roche spends aggressively on its pipeline (R&D and M&A) and is more successful than peers in...

2024-06-15 09:00:00 ET Summary There are always opportunities in this market for stocks despite high total market valuation. Gilead Sciences offers strong growth potential with a well-covered dividend yield of 4.8% and a promising pipeline. Enbridge provides stable income with...

2024-06-14 15:55:36 ET More on Bristol-Myers Squibb Company , Gilead Sciences, etc. Bristol-Myers Squibb: Move Investing Time Horizon To 2025, At Least Gilead Sciences, Inc. (GILD) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Bristol-Myers...

2024-06-14 15:15:06 ET RBC Capital analyst issues UNDERPERFORM recommendation for GILD on June 14, 2024 12:00PM ET. The previous analyst recommendation was Underperform. GILD was trading at $65.16 at issue of the analyst recommendation. The overall analyst consensus : BU...

2024-06-14 15:15:06 ET UBS analyst issues SECTOR PERFORM recommendation for GILD on June 14, 2024 12:00PM ET. The previous analyst recommendation was Sector Perform. GILD was trading at $65.16 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

2024-06-14 15:15:06 ET Evercore ISI analyst issues OUTPERFORM recommendation for GILD on June 14, 2024 11:39AM ET. The previous analyst recommendation was Outperform. GILD was trading at $65.07 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

2024-06-14 11:23:46 ET More on Gilead Sciences Gilead Sciences, Inc. (GILD) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Gilead Sciences, Inc. (GILD) Jefferies 2024 Global Healthcare Conference Gilead Sciences: Seriously Undervalued At Peak Pes...